Literature DB >> 34534131

Immune Profiling Demonstrates a Common Immune Signature of Delayed Acquired Immunodeficiency in Patients With Various Etiologies of Severe Injury.

Fabienne Venet1, Julien Textoris1, Sophie Blein1, Mary-Luz Rol2, Maxime Bodinier1, Bertrand Canard2, Pierre Cortez3, Boris Meunier1, Lionel K Tan4, Craig Tipple4, Laurence Quemeneur3, Frédéric Reynier2, Philippe Leissner2, Christophe Védrine2, Yves Bouffard1, Benjamin Delwarde1, Olivier Martin1, Thibaut Girardot1, Cyrille Truc1, Andrew D Griffiths5, Virginie Moucadel1, Alexandre Pachot1, Guillaume Monneret1, Thomas Rimmelé1.   

Abstract

OBJECTIVES: The host response plays a central role in the pathophysiology of sepsis and severe injuries. So far, no study has comprehensively described the overtime changes of the injury-induced immune profile in a large cohort of critically ill patients with different etiologies.
DESIGN: Prospective observational cohort study.
SETTING: Adult ICU in a University Hospital in Lyon, France. PATIENTS: Three hundred fifty-three septic, trauma, and surgical patients and 175 healthy volunteers were included in the REAnimation Low Immune Status Marker study.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Extensive immune profiling was performed by assessing cellular phenotypes and functions, protein, and messenger RNA levels at days 1-2, 3-4, and 5-7 after inclusion using a panel of 30 standardized immune markers. Using this immunomonitoring panel, no specificity in the immune profile was observed among septic, trauma, and surgical patients. This common injury-induced immune response was characterized by an initial adaptive (i.e., physiologic) response engaging all constituents of the immune system (pro- and anti-inflammatory cytokine releases, and innate and adaptive immune responses) but not associated with increased risk of secondary infections. In contrary, the persistence in a subgroup of patients of profound immune alterations at the end of the first week after admission was associated with increased risk of secondary infections independently of exposure to invasive devices. The combined monitoring of markers of pro-/anti-inflammatory, innate, and adaptive immune responses allowed a better enrichment of patients with risk of secondary infections in the selected population.
CONCLUSIONS: Using REAnimation Low Immune Status Marker immunomonitoring panel, we detected delayed injury-acquired immunodeficiency in a subgroup of severely injured patients independently of primary disease. Critically ill patients' immune status could be captured through the combined monitoring of a common panel of complementary markers of pro-/anti-inflammatory, innate, and adaptive immune responses. Such immune monitoring needs to be incorporated in larger study cohorts with more extensive immune surveillance to develop specific hypothesis allowing for identification of biological systems affecting altered immune function related to late infection in the setting of acute systemic injury.
Copyright © 2021 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 34534131     DOI: 10.1097/CCM.0000000000005270

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  7 in total

1.  A stratification strategy to predict secondary infection in critical illness-induced immune dysfunction: the REALIST score.

Authors:  Jan-Alexis Tremblay; Florian Peron; Louis Kreitmann; Julien Textoris; Karen Brengel-Pesce; Anne-Claire Lukaszewicz; Laurence Quemeneur; Christophe Vedrine; Lionel K Tan; Fabienne Venet; Thomas Rimmele; Guillaume Monneret
Journal:  Ann Intensive Care       Date:  2022-08-17       Impact factor: 10.318

Review 2.  Immunomonitoring of Monocyte and Neutrophil Function in Critically Ill Patients: From Sepsis and/or Trauma to COVID-19.

Authors:  Ivo Udovicic; Ivan Stanojevic; Dragan Djordjevic; Snjezana Zeba; Goran Rondovic; Tanja Abazovic; Srdjan Lazic; Danilo Vojvodic; Kendrick To; Dzihan Abazovic; Wasim Khan; Maja Surbatovic
Journal:  J Clin Med       Date:  2021-12-12       Impact factor: 4.241

3.  Concomitant Assessment of Monocyte HLA-DR Expression and Ex Vivo TNF-α Release as Markers of Adverse Outcome after Various Injuries-Insights from the REALISM Study.

Authors:  Frank Bidar; Maxime Bodinier; Fabienne Venet; Anne-Claire Lukaszewicz; Karen Brengel-Pesce; Filippo Conti; Laurence Quemeneur; Philippe Leissner; Lionel K Tan; Julien Textoris; Thomas Rimmelé; Guillaume Monneret
Journal:  J Clin Med       Date:  2021-12-24       Impact factor: 4.241

4.  Herpes DNAemia and TTV Viraemia in Intensive Care Unit Critically Ill Patients: A Single-Centre Prospective Longitudinal Study.

Authors:  François Mallet; Léa Diouf; Boris Meunier; Magali Perret; Frédéric Reynier; Philippe Leissner; Laurence Quemeneur; Andrew D Griffiths; Virginie Moucadel; Alexandre Pachot; Fabienne Venet; Guillaume Monneret; Alain Lepape; Thomas Rimmelé; Lionel K Tan; Karen Brengel-Pesce; Julien Textoris
Journal:  Front Immunol       Date:  2021-11-02       Impact factor: 7.561

5.  Monocyte Trajectories Endotypes Are Associated With Worsening in Septic Patients.

Authors:  Maxime Bodinier; Estelle Peronnet; Karen Brengel-Pesce; Filippo Conti; Thomas Rimmelé; Julien Textoris; Christophe Vedrine; Laurence Quemeneur; Andrew D Griffiths; Lionel K Tan; Fabienne Venet; Delphine Maucort-Boulch; Guillaume Monneret
Journal:  Front Immunol       Date:  2021-11-29       Impact factor: 7.561

6.  Nivolumab and interferon-γ rescue therapy to control mixed mould and bacterial superinfection after necrotizing fasciitis and septic shock.

Authors:  Anne-Claire Lukaszewicz; Fabienne Venet; André Boibieux; Mathilde Lherm; Bertrand Devigne; Guillaume Monneret
Journal:  Med Mycol Case Rep       Date:  2022-06-13

7.  Interferon gamma as an immune modulating adjunct therapy for invasive mucormycosis after severe burn - A case report.

Authors:  Dina M Tawfik; Caroline Dereux; Jan-Alexis Tremblay; Andre Boibieux; Fabienne Braye; Jean-Baptiste Cazauran; Meja Rabodonirina; Elisabeth Cerrato; Audrey Guichard; Fabienne Venet; Guillaume Monneret; Didier Payen; Anne-Claire Lukaszewicz; Julien Textoris
Journal:  Front Immunol       Date:  2022-08-22       Impact factor: 8.786

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.